Variants in the PPARγ gene affect fatty acid and glycerol metabolism in familial combined hyperlipidemia

Molecular Genetics and Metabolism

Volumn 80, Issue 3, 2003, Pages 296-301

  Eurlings, Petra M H ^a   Van Der Kallen, Carla J H ^a   Vermeulen, Vicky M M J ^a   De Bruin, Tjerk W A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLYCEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ADULT; ALLELISM; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; EVALUATION; FAMILIAL COMBINED HYPERLIPIDEMIA; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; BLOOD; CASE CONTROL STUDY; FAMILIAL HYPERLIPEMIA; GENETICS; METABOLISM; MIDDLE AGED; QUANTITATIVE TRAIT LOCUS;

ADULT; CASE-CONTROL STUDIES; FATTY ACIDS; FEMALE; GENE FREQUENCY; GLYCEROL; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; MALE; MIDDLE AGED; QUANTITATIVE TRAIT LOCI; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 0142154034     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(03)00138-0     Document Type: Article

References (35)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52:1973;1544-1568.
2. Voors-Pette C., de Bruin T.W.A. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 157:2001;481-489.
3. Pihlajamaki J., Karjalainen L., Karhapaa P., Vauhkonen I., Laakso M. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler. Thromb. Vasc. Biol. 20:2000;164-170.
4. Castro-Cabezas M., de Bruin T.W.A., de Valk H.W., Shoulders C.C., Jansen H., Erkelens D.W. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92:1993;160-168.
5. Aitman T.J., Godsland I.F., Farren B., Crook D., Wong H.J., Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;748-754.
6. Bredie S.J., Tack C.J., Smits P., Stalenhoef A.F. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler. Thromb. Vasc. Biol. 17:1997;1465-1471.
7. Karjalainen L., Pihlajamaki J., Karhapaa P., Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Arterioscler. Thromb. Vasc. Biol. 18:1998;1548-1553.
8. van der Kallen C.J.H., Voors-Pette C., Bouwman F.G., Keizer H.A., Lu J.Y., van de Hulst R.R.W.J., Bianchi R., Janssen M.-J., Keulen E.T.P., Boeckx W.D., Rotter J.I., de Bruin T.W.A. Evidence of insulin resistant lipid metabolism of adipose tissue in familial combined hyperlipidemia, but not in type 2 diabetes. Atherosclerosis. 164:2002;337-346.
9. Reynisdottir S., Eriksson M., Angelin B., Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J. Clin. Invest. 95:1995;2161-2169.
10. Meijssen S., Castro-Cabezas M., Twickler T.B., Jansen H., Erkelens D.W. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J. Lipid Res. 41:2000;1096-1102.
11. Sniderman A.D., Cianflone K., Arner P., Summers L.K., Frayn K.N. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 18:1998;147-151.
12. Babirak S.P., Brown B.G., Brunzell J.D. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 12:1992;1176-1183.
13. Pajukanta P., Nuotio I., Terwilliger J.D., Porkka K.V., Ylitalo K., Pihlajamaki J., Suomalainen A.J., Syvanen A.C., Lehtimaki T., Viikari J.S., Laakso M., Taskinen M.R., Ehnholm C., Peltonen L. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat. Genet. 18:1998;369-373.
14. Aouizerat B.E., Allayee H., Cantor R.M., Davis R.C., Lanning C.D., Wen P.Z., Dallinga-Thie G.M., de Bruin T.W.A., Rotter J.I., Lusis A.J. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am. J. Hum. Genet. 65:1999;397-412.
15. Allayee H., de Bruin T.W.A., Dominguez K.M., Cheng L.S.-C., Ipp E., Cantor R.M., Krass K.L., Keulen E.T.P., Aouizerat B.E., Lusis A.J., Rotter J.I. Genome-scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension. 38:2001;773-778.
16. van der Kallen C.J.H., Cantor R.M., van Greevenbroek M.M.J., Geurts J.M.W., Bouwman F.G., Aouizerat B.E., Allayee H., Buurman W.A., Lusis A.J., Rotter J.I., de Bruin T.W.A. Genome scan for adiposity in Dutch dyslipidemic families reveals novel quantitive trait loci for leptin, body mass index and soluble tumor necrosis factor receptor superfamily 1A. Int. J. Obes. Relat. Metab. Disord. 24:2000;1381-1391.
17. de Bruin T.W.A., Mailly F., van Barlingen H., Fisher R., Castro-Cabezas M., Talmud P., Dallinga-Thie G.M., Humphries S.E. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur. J. Clin. Invest. 26:1996;631-639.
18. Dallinga-Thie G.M., van Linde-Sibenius T.M., Rotter J.I., Cantor R.M., Bu X., Lusis A.J., de Bruin T.W.A. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J. Clin. Invest. 99:1997;953-961.
19. Pihlajamaki J., Miettinen R., Valve R., Karjalainen L., Kuusisto J., Deeb S., Auwerx J., Laakso M. The Pro12Ala substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in non-diabetic elderly subjects with dyslipidemia. Atherosclerosis. 151:2000;567-574.
20. Eurlings P.M.H., van der Kallen C.J.H., Geurts J.M.W., Flavell D.M., de Bruin T.W.A. Identification of the PPARA locus on chromosome 22q13.3 as a modifier gene in familial combined hyperlipidemia. Mol. Genet. Metab. 77:2002;274-281.
21. Pajukanta P., Porkka K.V., Antikainen M., Taskinen M.R., Perola M., Murtomaki R.S., Ehnholm S., Nuotio I., Suurinkeroinen L., Lahdenkari A.T., Syvanen A.C., Viikari J.S., Ehnholm C., Peltonen L. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler. Thromb. Vasc. Biol. 17:1997;841-850.
22. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J. Lipid Res. 43:2002;177-186.
23. Rosen E.D., Walkey C.J., Puigserver P., Spiegelman B.M. Transcriptional regulation of adipogenesis. Genes Dev. 14:2000;1293-1307.
24. Guan H.P., Li Y., Jensen M.V., Newgard C.B., Steppan C.M., Lazar M.A. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8:2002;1122-1128.
25. Aouizerat B.E., Allayee H., Cantor R.M., Dallinga-Thie G.M., Lanning C.D., de Bruin T.W.A., Lusis A.J., Rotter J.I. Linkage of a candidate gene locus to familial combined hyperlipidemia - Lecithin: cholesterol acyltransferase on 16q. Arterioscler. Thromb. Vasc. Biol. 19:1999;2730-2736.
26. Geurts J.M.W., Janssen R.G.J.H., van Greevenbroek M.M.J., van der Kallen C.J.H., Cantor R.M., Bu X., Aouizerat B.E., Allayee H., Rotter J.I., de Bruin T.W.A. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum. Mol. Genet. 9:2000;2067-2074.
27. http://www.gdb.org.
28. Ek J., Urhammer S.A., Sorensen T.I., Andersen T., Auwerx J., Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia. 42:1999;892-895.
29. Wang X.L., Oosterhof J., Duarte N. Peroxisome proliferator-activated receptor gamma C161. → T polymorphism and coronary artery disease Cardiovasc. Res. 44:1999;588-594.
30. Vaccaro O., Mancini F.P., Ruffa G., Sabatino L., Iovine C., Masulli M., Colantuoni V., Riccardi G. Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene in healthy individuals. Clin. Endocrinol. (Oxf.). 57:2002;481-486.
31. Hihi A.K., Michalik L., Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell. Mol. Life Sci. 59:2002;790-798.
32. Evans R.M., Lee C., Wang Y., Yu R., Chawla A., Hevener A., He W., Barak Y., Olson P., Olefsky J. PPARgamma and delta in obesity. Diabetes and Heart Disease, Keystone Symposia: PPARs: Transcriptional Regulators of Metabolism and Metabolic Disease. 2003;36.
33. Savage D.B., Agostini M., Barroso I., Gurnell M., Luan J., Meirhaeghe A., Harding A.H., Ihrke G., Rajanayagam O., Soos M.A., George S., Berger D., Thomas E.L., Bell J.D., Meeran K., Ross R.J., Vidal-Puig A., Wareham N.J., O'Rahilly S., Chatterjee V.K., Schafer A.J. Digenic inheritance of severe insulin resistance in a human pedigree. Nat. Genet. 31:2002;379-384.
34. Schoonjans K., Martin G., Staels B., Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8:1997;159-166.
35. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 42:1999;1033-1049.